Translationally, the panRAF inhibitor naporafenib combined with trametinib produced preliminary antitumor activity in a phase Ib expansion cohort of previously treated NRAS‐mutant melanoma, catalyzing the ongoing SEACRAFT‐2 pivotal phase III trial (NCT06346067) (de Braud et al. 2023; Erasca 2025). Here, NRAS is linked to melanoma.